Abstract:Objectives: Tissue engineered vascular grafts with long-term patency are in great need in the clinics, for which smooth muscle cells (SMCs) are essential. Recently several laboratories have established methods to obtain SMCs from embryonic stem cells or iPS cells. However, the mechanisms of stem cell differentiation are not fully understood. And also it is hard to obtain a large number of SMCs with higher purity. To solve these issues, we take the advantage of mesenchymal stem cells (MSCs) from human umbilical cord that were cultivated and differentiated in vitro. Methods: MSCs from human umbilical cord were cultivated and differentiated to vascular lineages. Signal pathways involved in stem cell differentiation were studied using Western blot, siRNA, PCR, immunoprecipation and transfection. For vascular tissue engineering, stem cell-derived SMCs were applied to decelularized scaffold to create the vessels in a Bioreactor. Results: In response to TGFβ1 stimulation, MSCs were abundantly expressing SMC markers including αSMA, SM22, calponin and SMMHC at the gene and protein levels. Functionally, differentiated SMCs displayed a contraction ability in vitro and formed vessels in matrigel plug assay SCID mice. Micro-RNA (miR) array analysis showed the upregulation of miR-503 and the downregulation of miR-222-5p at early time points after TGFβ1 treatment, which was confirmed by TaqMan microRNA assay. Mechanistically, miR-503 was demonstrated to promote SMC differentiation through directly targeting Smad7, a negative regulator of TGFβ1 Smad-related signaling pathways. The expression of miR-503 was Smad4-dependent and Smad4 was enriched at the promoter region of miR-503. In addition, miR-222-5p inhibited SMC differentiation through targeting ROCK2 and αSMA 3’-UTR. Finally, SMCs differentiated from stem cells exhibited the ability to migrate into decellularized mouse aorta and gave rise to vascular graft with smooth muscle layer. Conclusions: We established a method to produce a large number of human SMCs from MSCs, which demonstrated the potential of utilizing the cells to generate vascular grafts. And we provide the mechanistic data demonstrating the impact of miRNA-503/222-5p on TGFβ1-mediated signaling in SMC differentiation from stem cells.

Patient-specific Cardiovascular Progenitor Cells Derived from Integration-Free Induced Pluripotent Stem Cells for Vascular Tissue Regeneration

Derivation of Functional Smooth Muscle Cells from Integration-Free Induced Pluripotent Stem Cells Through Cardiovascular Progenitor Cell Intermediates for Vascular Regeneration

Engineering Vascular Tissue with Functional Smooth Muscle Cells Derived from Human Ips Cells and Nanofibrous Scaffolds.

Abstract 302: Generation of Patient-Specific Tissue-Engineered Blood Vessels from Nonintegrated Induced Pluripotent Stem Cells

Induction of Differentiation of CD34+ Cells in Vitro and Application in Endothelialization of Blood Vessel Prostheses

Generation, expansion, and differentiation of cardiovascular progenitor cells from human pluripotent stem cells.

Differentiation of smooth muscle progenitor cells in peripheral blood and its application in tissue engineered blood vessels

Highly efficient induction and long-term maintenance of multipotent cardiovascular progenitors from human pluripotent stem cells under defined conditions

Generation of cardiac valve endocardial like cells from human pluripotent stem cells

Use of human aortic extracellular matrix as a scaffold for construction of a patient-specific tissue engineered vascular patch.

Generation and Grafting of Tissue-Engineered Vessels in a Mouse Model.

Expandable Cardiovascular Progenitor Cells Reprogrammed from Fibroblasts

The effect of stromal cell-derived factor-1α/heparin coating of biodegradable vascular grafts on the recruitment of both endothelial and smooth muscle progenitor cells for accelerated regeneration.

Hierarchically Vascularized and Implantable Tissue Constructs created through Angiogenesis from Tissue-Engineered Vascular Grafts

Abstract 650: Stem Cell-derived SMCs Are Useful for Vascular Tissue Engineering

C-Kit+ Progenitors Generate Vascular Cells for Tissue-Engineered Grafts Through Modulation of the Wnt/Klf4 Pathway.

Generation and characterization of cardiac valve endothelial-like cells from human pluripotent stem cells

Transdifferentiated Human Vascular Smooth Muscle Cells Are A New Potential Cell Source for Endothelial Regeneration

Construction of Vascular Tissues with Macro-Porous Nano-Fibrous Scaffolds and Smooth Muscle Cells Enriched from Differentiated Embryonic Stem Cells.

Construction of Tissue-Engineered Vascular Grafts with Enhanced Patency by Integrating Heparin, Cell-Adhesive Peptide, and Carbon Monoxide Nanogenerators into Acellular Blood Vessels

Fabrication of Tissue-Engineered Vascular Grafts with Stem Cells and Stem Cell-Derived Vascular Cells.